Pfizer confirms $99bn AstraZeneca bid, continues courtship
This article was originally published in Scrip
AstraZeneca's share price opened up 12.6% on 28 April after Pfizer confirmed that it had made a £58.7bn ($99bn) takeover bid for the UK firm. Pfizer is still keen to consummate a cash and shares merger, which would yield tax benefits, opportunities to cut costs, and a shared pipeline with new possibilities to develop combination products, for example in immuno-oncology.
You may also be interested in...
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.
Sanofi pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.